Login to Your Account

In The Clinic NEWS

With the bulk of Galena Biopharma Inc.'s value riding on cancer vaccine Neuvax, the firm's shares predictably plunged to a new 52-week low Wednesday as an IDMC recommended the PRESENT phase III study in breast cancer be stopped.

A serious new case of jaundice that developed during a Regulus Therapeutics Inc. study of RG-101 for the treatment of chronic HCV triggered the FDA to issue a verbal clinical hold on the program, sending company shares (NASDAQ:RGLS) down 49.3 percent to $2.54 on Tuesday.

NEW DELHI – Working with a U.S. partner, one of India's most active biopharma companies, Biocon Ltd., is moving forward on late-stage trials for a drug aimed at treating a common eye disorder for which there is no marketed treatment.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: